ESGE Days 2026: Endoscopic Procedure Surpasses Oral Semaglutide in Short-Term Weight Loss

A recent study presented at ESGE Days 2026 in Milan reveals that endoscopic sleeve gastroplasty (ESG) leads to greater short-term weight loss compared to oral semaglutide in obese adults. This retrospective cohort study, involving 150 patients, showed a mean weight loss of 12.7% for ESG versus 8.7% for those on semaglutide after six months, marking a significant 4.0% difference.

Both groups showed similar rates of mild gastrointestinal side effects with no serious complications. Clinically meaningful weight loss was more common in the ESG group; 70% lost at least 10% of their body weight compared to 43% in the semaglutide group. ESG, a minimally invasive procedure, contrasts with semaglutide's pharmacological approach, offering new insights into obesity treatment options.

Dr. Nitin G. Jagtap emphasized personalized treatment decisions, urging for matching therapies to patient needs and preferences. Despite the robust findings, individual treatment choices should factor in access and adherence.